EQRx Pharmaceutical Company
EQRx is a new type of pharmaceutical company committed to developing and delivering innovative medicines to patients around the world at radically lower prices.
Launched in January 2020, EQRx is purpose-built, at scale, with a growing catalog of medicines in development in high-cost drug categories and a growing number of emerging partnerships with leading payers and providers.
Every day, people are diagnosed with life-changing conditions, but often cannot afford the medicines they need.
Through leveraging cutting-edge science and technology and strategic partnerships with stakeholders from across the healthcare system, EQRx aims to provide innovative, patent-protected medicines more efficiently and cost-effectively than ever before.
This is a vision aligned with that long held by Jameel Family and most recently expressed by the creation of Abdul Latif Jameel Health, and in late-2020, the JIMCO Life Sciences fund became an enthusiastic investor in EQRx and further increased our commitment in 2021.
EQRx has already made significant progress toward their mission to make innovative medicines available at radically lower prices, starting with two potential therapies for the treatment of lung cancer. It now has a portfolio of over 10 programs.
In December 2021, EQRx debuted as publicly traded company following a business combination with CM Life Sciences III, the combined company EQRX Inc. trades on Nasdaq Global Market under ticker ‘EQRX’ and ‘EQRXW’.
Explore other partners
